News ArchivesRead News
Tumours found in rats given stem cells during Parkinson’s study
Thursday October 26, 2006
October 23, 2006 (CBC News) - A potential leap in the treatment of Parkinson’s disease has been tempered with a setback as rats injected with embryonic stem cells were essentially cured of Parkinson’s-like symptoms, but soon developed brain tumours.
When researchers at the University of Rochester transplanted human embryonic stem (HES) cells into the rats, "the implants yielded a significant, substantial and long-lasting restitution of motor function," according to a study published Monday in the online journal of Nature Medicine.
But after 10 weeks into the trial, the scientists discovered the tumours had begun to grow in every rat.
The findings are considered a blow to plans to use HES cells to grow tissues for human transplant.
Stem cells can be thought of as blank slates or cells that have yet to become specialized. They have the ability to become any type of cell to form skin, bones, organs or other body parts.
In particular, researchers have seen the potential for HES cell therapy in curing Parkinson’s because the disease requires only a single cell type that produces dopamine. Dopamine is a neurotransmitter that carries signals between neurons (brain cells).
The brain cells containing dopamine become injured or die in a Parkinson’s patient, which often leads to the person being unable to control physical movements, or they suffer from tremors.
Canada and several other countries have approved strict laws that limit research on stem cells from human embryos.
Recent NewsSep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show
Aug 14 - 16 Tips to Increase Your Mobility Confidence While Living With Parkinson’s Disease
Aug 10 - Boxers are fighting back against Parkinson’s
Aug 9 - Parkinson’s Experiment to Be Aboard Next Flight to International Space Station
Aug 9 - Parkinson’s Disease and Sleeping with the Enemy
Aug 7 - The Importance of Oral Health in Parkinson’s Disease
Aug 7 - Researchers Gain Better Insight Into Alpha-Synuclein’s Role in Parkinson’s Disease
Jul 31 - New Digital Cognitive Assessment Tool Receives Positive FDA Review
Jul 20 - Parkinson’s DREAM Challenge Uses Mobile Sensor Data to Monitor Health Based on Movement